Ignite Creation Date:
2025-12-25 @ 4:09 AM
Ignite Modification Date:
2026-03-04 @ 8:56 PM
Study NCT ID:
NCT05147220
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2021-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsing Multiple Sclerosis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | MS | View |
| None | RMS | View |
| None | RRMS | View |
| None | active secondary progressive multiple sclerosis SPMS | View |
| None | remibrutinib | View |
| None | LOU064 | View |
| None | teriflunomide | View |
| None | adult | View |
| None | relapse | View |
| None | Expanded Disability Status Scale | View |
| None | T2 lesions | View |
| None | T1 lesions | View |
| None | GD- enhancing MRI | View |
| None | Neurofilament light chain | View |
| None | McDonald diagnostic criteria | View |